01.08.10
An alliance between Probi, a leading player in probiotics research and a partner of Institut Rosell, and Jarrow Formulas, now gives the nutritional supplement company the right to sell a dietary supplement that contains Probi’s bacteria, Lp299v, exclusively to U.S. health food stores. The Jarrow Formulas’ product Ideal Bowel Support (IBS) 299v will launch in the first quarter of 2010.
Probi’s probiotic bacteria Lp299v has been shown in clinical trials to help people suffering from symptoms associated with Irritable Bowel Syndrome (IBS), which include diarrhea, constipation and abdominal cramps. IBS affects up to 55 million Americans and mostly women.
“The agreement with Jarrow Formulas is another very important step in our company’s strategy to make Lp299v available on a global scale,” said Michael Oredsson, CEO at Probi. “The U.S. is a big, important and growing market for probiotic dietary supplements. We are very pleased to launch Lp299v in the U.S. health food channel. Jarrow Formulas is one of the leading players in the probiotic category. Jarrow’s mission is to promote optimal health with high quality, effective, affordable and ‘cutting edge’ formulations, which are based on sound scientific research data. This philosophy is in line with the high quality of Lp299v.”
The U.S. probiotic dietary supplement market is estimated at approximately $500 million annually and is expected to see further growth as more high quality and clinically documented products, such as Jarrow Formulas’ product IBS 299v, are launched. Dietary supplements that contain Probi’s probiotics are now sold or in the process of being launched in more than 30 countries worldwide.
“We will continue to work both independently and together with Institut Rosell to further expand distribution and sales of dietary supplements based on Lp299v,” said Mr. Oredsson.
Probi’s probiotic bacteria Lp299v has been shown in clinical trials to help people suffering from symptoms associated with Irritable Bowel Syndrome (IBS), which include diarrhea, constipation and abdominal cramps. IBS affects up to 55 million Americans and mostly women.
“The agreement with Jarrow Formulas is another very important step in our company’s strategy to make Lp299v available on a global scale,” said Michael Oredsson, CEO at Probi. “The U.S. is a big, important and growing market for probiotic dietary supplements. We are very pleased to launch Lp299v in the U.S. health food channel. Jarrow Formulas is one of the leading players in the probiotic category. Jarrow’s mission is to promote optimal health with high quality, effective, affordable and ‘cutting edge’ formulations, which are based on sound scientific research data. This philosophy is in line with the high quality of Lp299v.”
The U.S. probiotic dietary supplement market is estimated at approximately $500 million annually and is expected to see further growth as more high quality and clinically documented products, such as Jarrow Formulas’ product IBS 299v, are launched. Dietary supplements that contain Probi’s probiotics are now sold or in the process of being launched in more than 30 countries worldwide.
“We will continue to work both independently and together with Institut Rosell to further expand distribution and sales of dietary supplements based on Lp299v,” said Mr. Oredsson.